Volume 8, Issue 27 (3-2002)                   RJMS 2002, 8(27): 541-547 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bazzazi H, Fateminasab F, Entezami K, Salek moghaddam A, Shahghasempour S. EXPRESSION OF HLA CLASS-IA ON TUMOR CELL LINES AND THEIR SUSCEPTIBILITY TO NK CELL. RJMS 2002; 8 (27) :541-547
URL: http://rjms.iums.ac.ir/article-1-387-en.html
Abstract:   (9385 Views)
ABSTRACT Natural Killer cells (NKs), are considered an important first line of defence and were originally defined by their ability to kill certain tumor cells and virally infected cells. Our aim is to study expression of HLA class-Ia on tumor cell lines and their susceptibility of NK cells. In this study MDA-MB-468 tumor cell line (NCB1, C208) That derived from human breast adenocarcinoma, is selected as a model which expresses total alleles of HLA class I. To test HLA class I expression, we used the F.I.T.C conjugatedm Ab W6/32 which recognize assembled HLA-A, B and C locus products. Surface expression of HLA class I on the cell line are determined with single- color flowcytometry analysis. NK cells are obtained from PBL of healthy donors. Results of our study indicate that expression of HLA class I molecules on MDA- MB- 468 Tumor cell line are increased after IFN-γ Treatment. Cytolytic activity of NK cells have direct correlation (r =1) with up- regulation of HLA class I expression on the MDA- MB- 468 tumor cell line. Therefore, on the basis of this results, we suggest that, on the surface of NK cells may exsist activating receptors that recognize allogenic HLA class I molecules and/or non HLA class I ligand that is upregulated by IFN- & treatment, and cause lysis of target cells.
Full-Text [PDF 281 kb]   (3237 Downloads)    
Type of Study: Research | Subject: Immunology

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb